Table 1.
Characterization of the primary cohort (n = 6644)
| Distribution | n | |
|---|---|---|
| Age, years (mean ± SD) | 62.0 ± 15.1 (25th percentile, 51.7; median, 63.0; 75th percentile, 74.2) | 6644 |
| Gender | ||
| male, % | 54.2 | 3603 |
| female, % | 45.8 | 3041 |
| Race | ||
| white, % | 57.7 | 3830 |
| nonwhite, % | 42.4 | 2814 |
| BMI, kg/m2 (mean ± SD) | 27.9 ± 7.6 | 6643 |
| ≤20, % | 9.7 | 642 |
| 20-25, % | 30.8 | 2044 |
| 25-30, % | 28.9 | 1919 |
| 30-35, % | 15.9 | 1053 |
| >35, % | 14.8 | 985 |
| Comorbidities, % present | ||
| diabetes mellitus | 24.8 | 1648 |
| hypertension | 40.4 | 2682 |
| arterial diseasea | 14.3 | 951 |
| coronary artery disease | 9.8 | 654 |
| peripheral vascular disease | 5.1 | 337 |
| cerebrovascular disease | 3.1 | 207 |
| congestive heart failure | 12 | 797 |
| cancer | 2.9 | 193 |
| Laboratory measures (3-month mean ± SD)b | ||
| urea reduction ratio, % | 71.3 ± 6.8 | 6514 |
| Kt/V | 1.33 ± 0.27 | 6438 |
| albumin, g/dl | 3.7 ± 0.4 | 6644 |
| bicarbonate, mEq/L | 23.8 ± 2.9 | 6609 |
| calcium, mg/dl | 9.0 ± 0.6 | 6637 |
| phosphate, mg/dl | 5.4 ± 1.3 | 6644 |
| creatinine, mg/dl | 7.4 ± 2.9 | 6559 |
| intact PTH, pg/ml | 176 ± 158 | 6390 |
| Laboratory measures (6-month mean ± SD)c | ||
| ferritin, ng/ml | 380 ± 414 | 6631 |
| transferrin saturation, % | 24.9 ± 6.7 | 6596 |
| Treatment measuresc | ||
| cumulative 6-month intravenous iron dose, mg | 943 ± 798 | 6452 |
| cumulative 6-month erythropoietin dose, U | 559,700 ± 351,000 | 6613 |
| average no. of doses per subject | 60.5 ± 13.3 | 6613 |
| average dose per treatment | 9540 ± 7580 | 6613 |
a
Arterial disease is not mutually exclusive.
b
Averaged over dialysis days 91 to 180.
c
Considered over dialysis days 0 to 180.